U.S. markets closed

Abbott Laboratories (ABL.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
89.25+0.06 (+0.07%)
At close: 7:25PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close89.19
Open89.69
Bid0.00 x 90000
Ask0.00 x 90000
Day's Range89.25 - 90.57
52 Week Range59.00 - 98.00
Volume224
Avg. Volume292
Market Cap158.478B
Beta (5Y Monthly)0.95
PE Ratio (TTM)51.56
EPS (TTM)1.73
Earnings DateN/A
Forward Dividend & Yield1.22 (1.37%)
Ex-Dividend DateOct 14, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Abbott Wins European Approval for Latest MitraClip Heart Valve Device
      Motley Fool

      Abbott Wins European Approval for Latest MitraClip Heart Valve Device

      Abbott Laboratories (NYSE: ABT) has scored a fresh victory across the Atlantic Ocean. The company announced Monday that it has been granted a CE Mark for its MitraClip G4, the latest version of its popular heart valve replacement device, which means it is approved for use in the countries of the European Union. The G4 had already been approved for use in the U.S. by the Food and Drug Administration.

    • Reuters

      Lufthansa plans rapid COVID-19 testing starting October -executive

      Deutsche Lufthansa AG plans to start making rapid COVID-19 antigen tests available to passengers in October and is weighing the option of opening test centres at airports in the United States and Canada, a company executive said on Tuesday. While the aviation industry has largely backed the use of Polymerase Chain Reaction (PCR) tests which take several hours to process in a lab, airline trade group IATA on Tuesday touted antigen tests that can be processed on site and typically give results within about 15 minutes. "You know that companies like Abbott or Roche are bringing these tests to the market and we are definitely looking into this," said Bjoern Becker, senior director, product management, ground & digital services for the Lufthansa Group.

    • Abbott Tacks On Massive Coronavirus Test Growth — But Is ABT Stock A Buy?
      Investor's Business Daily

      Abbott Tacks On Massive Coronavirus Test Growth — But Is ABT Stock A Buy?

      Medical company Abbott has now launched a handful of coronavirus tests, and the U.S. is paying $750 million for 150 million of the most recently approved tests. So, is ABT stock a buy now?